Shigella vaccines are being developed to control the rising burden of shigellosis globally. Shigella infections are common in developing countries with poor sanitation and lack of clean drinking water. The currently available Shigella vaccines are focused on protecting young children from the severe health complications of shigellosis such as diarrhea, abdominal pain and fever.
The Shigella Vaccines Market is estimated to be valued at US$ 574.20 Mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The shigella vaccines market is expected to witness significant growth over the forecast period owing to two major drivers. Firstly, the increasing R&D investments by government organizations and private players to develop more effective anti-shigella vaccines is positively impacting the market. Various companies are conducting clinical trials of candidate vaccines to assess safety and efficacy. Secondly, the rising prevalence of antimicrobial resistance among shigella strains has necessitated the development of vaccines as an alternative preventive strategy for shigellosis control. The growing threat of untreatable shigellosis infections is attracting research funding for vaccine candidates targeting multidrug resistant shigella serotypes. This is expected to fuel market revenue growth during the forecast period.
The Shigella vaccines market is segmented into monovalent shigella conjugate vaccine and combination shigella conjugate vaccine. The combination shigella conjugate vaccine segment is dominating the market owing to the high demand for combination vaccine that prevents against multiple types of shigella serotypes in a single dose.
Political: Government initiatives and regulations to curb shigella infections are driving the research and development of shigella vaccines.
Economic: Rising healthcare spending on the development of new vaccines is fuelling the shigella vaccines market growth.
Social: Increasing awareness regarding the severity of shigella infections is propelling the demand for preventive shigella vaccines.
Technological: Advancements in vaccine manufacturing technologies are enabling the development of effective shigella vaccines with long-lasting immunity.
The global Shigella vaccines market is expected to witness high growth, exhibiting CAGR of 6.4% over the forecast period, due to increasing prevalence of shigella infections globally. The market size for shigella vaccines is estimated to reach US$ 989.81 mn by 2030 from US$ 574.20 mn in 2023.
Regional analysis: Asia Pacific is expected to dominate the shigella vaccines market owing to the high shigella disease burden in densely populated countries like India and China. Southeast Asian countries are witnessing rising shigella cases and hence represent a lucrative market for shigella vaccines.
Key players operating in the shigella vaccines market are MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc. MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.’s Shyne is the only shigella conjugate vaccine approved for use till date. Novartis and GlaxoSmithKline are engaged in developing novel shigella vaccines.
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it